Sinopharm Group Co (1099) Stock Statistics & Valuation Metrics

Sinopharm Group Co has a market cap or net worth of HK$55.33B. The enterprise value is HK$95.10B.

Sinopharm Group Co has 1,341,810,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sinopharm Group Co’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 5.63%.

The current PE Ratio of Sinopharm Group Co is 7.6. Sinopharm Group Co’s PEG ratio is 5.74.

In the last 12 months, Sinopharm Group Co had revenue of 575.17B and earned 7.16B in profits. Earnings per share was 2.29.

In the last 12 months, operating cash flow was 12.05B and capital expenditures -1.55B, giving a free cash flow of 10.50B billion.

Sinopharm Group Co pays an annual dividend of HK$0.739, resulting in a dividend yield of 3.75%

Sinopharm Group Co upcoming earnings date is Aug 31, 2026, TBA (Not Confirmed).

Sinopharm Group Co as a current ratio of 1.41, with Debt / Equity ratio of 129.33%

In the past 12 months, Sinopharm Group Co has paid 3.97B in taxes.

Sinopharm Group Co EV to EBITDA ratio is 5.27, with an EV/FCF ratio of 8.11.

Sinopharm Group Co has HK$61.59B in cash and marketable securities with HK$108.63B in debt, giving a net cash position of -HK$47.04B billion.

Gross margin is 7.32%, with operating margin of 2.79%, and net profit margin of 1.24%.

The average price target for Sinopharm Group Co is HK$22.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy